Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio - LARVOL DELTA

Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Iongen Therapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

The impact of the DiI fluorescent probe on the in vivo fate of paclitaxel-loaded methoxy polyethylene glycol-block-poly (d,l-lactide) micelles. (PubMed, Drug Metab Dispos) - "SIGNIFICANCE STATEMENT: This study reveals that the common fluorescent probe DiI significantly alters the in vivo fate of paclitaxel-loaded polymeric micelles by accelerating drug release, competing for plasma protein binding, and inhibiting carrier elimination. These findings highlight the critical need for rigorous validation when using fluorescent probes to track nanomedicines."

Journal • Preclinical

Recapitulating In Vivo Pharmacokinetics and Size-Dependent Nanomedicine Delivery in a Microfluidic Platform. (PubMed, Adv Sci (Weinh)) - "Using paclitaxel-loaded polymeric micelles in a non-small cell lung cancer model, the platform reproduces in vivo-like concentration-time profiles and recapitulates formulation-dependent therapeutic responses. The system further captures size-dependent delivery patterns associated with enhanced permeability and retention. By linking systemic pharmacokinetics with tumor-level transport and response, this platform establishes a predictive framework for evaluating nanomedicine performance beyond conventional static assays."

Journal • PK/PD data • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Iongen Therapeutics Co., Ltd.

New P1 trial • Pain

Clinical efficacy and safety of genexol PM in patients with solid tumours: A retrospective observational study in Indian patients (ESMO Asia 2025) - "Paclitaxel monotherapy was given in 23.7%...Bevacizumab (n=15) was the most used targeted therapy followed by Trastuzumab (n=6) and Ramucirumab (n=5)... These results suggest that Genexol PM cremophor-free formulation is a promising approach in multiple solid malignancies and generally well tolerated among Indian patients."

Observational data • Retrospective data • Breast Cancer • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Recent advances in polymer-based nanoparticles: current strategies and translational challenges in cancer therapy. (PubMed, J Chemother) - "FDA-approved formulations such as Abraxane® (albumin-bound paclitaxel) and clinical candidates like Genexol-PM® (polymeric micelles) highlight the translational relevance of PNPs. This review consolidates advancements in polymeric nanocarriers, including nanospheres, nano-capsules and hybrid composites, while addressing limitations in regulatory approval and personalized oncology integration. This study shows that nanoparticle-based cancer therapeutics hold immense potential to improve treatment efficacy and patient outcomes in clinical oncology."

Journal • Review • Oncology

Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. (clinicaltrials.gov) - P2 | N=38 | Not yet recruiting | Sponsor: Jiangsu Cancer Institute & Hospital

New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Nanoparticle polymeric micellar paclitaxel combined with gemcitabine in first-line treatment of patients with metastatic pancreatic cancer: A single-arm, phase II clinical study. (ASCO 2025) - P4 | "This Phase II clinical trial evaluated the efficacy and safety of nanoparticle polymeric micellar paclitaxel(pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer(mPC). In conclusion, the combination of pm-Pac and gemcitabine, as the first-line therapy for mPC, exhibited favorable tolerability and encouraging clinical efficacy. Larger randomized controlled trials are necessary to validate these preliminary findings."

Clinical • Metastases • P2 data • Anemia • Neutropenia • Oncology • Pain • Pancreatic Cancer • Solid Tumor

A Phase 1 Study to Assess the Safety of IGT001 Intravitreal Injection (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

New P1 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Laminarin-coated Genexol-PM pH sensitive nanomicelles targeting miR-620/IRF2BP2 axis for inhibition of cell proliferation and induction of apoptosis in Invitro thyroid carcinoma. (PubMed, Int J Biol Macromol) - "By leveraging both oxidative stress mechanisms and apoptosis induction, BP@PLGA/PLA offers a promising approach for overcoming limitations in conventional chemotherapy. These findings underscore the potential of pH-responsive nanomicelles in precision oncology, offering improved drug delivery, enhanced therapeutic index, and a more effective strategy for combating drug-resistant cancers."

Journal • Preclinical • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

A single-center, open, single-arm Phase II exploratory clinical study of Genexol-PM combined with standard postoperative chemoradiotherapy for postoperative adjuvant treatment of glioblastoma multiforme (ChiCTR) - P4 | N=20 | Sponsor: Jiangsu Province Hospital; Jiangsu Province Hospital

New P4 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Impact of Open Surgical Descending Repair on Aortic Stiffness in an Ex Vivo Porcine Model. (PubMed, Ann Vasc Surg) - "Subsequently, 10cm proximal descending aorta was excised and replaced with Dacron® (IGK0018-40S)...The stable systolic pressure and decreased diastolic pressure, after surgery, led to an increased pulse pressure (Type I: 49 to 59mmHg,p<.001; Type III: 49 to 58mmHg;p<.001) Surgical interposition grafting of the proximal descending aorta increases aortic PWV, increases pulse pressure, and decreases diastolic blood pressure. These findings might be important for the long-term results of patients undergoing surgical treatment of aortic diseases."

Journal • Preclinical • Cardiovascular

Self-Assembled Micelles Based on Ginsenoside Rg5 for the Targeted Treatment of PTX-Resistant Tumors. (PubMed, Mol Pharm) - "However, the poor water solubility, inadequate specific targeting ability, multidrug resistance, and severe neurotoxicity are far from being fully resolved, despite diverse PTX formulations in the market, such as the gold-standard PTX albumin nanoparticle (Abraxane) and polymer micelles (Genexol-PM). With the aid of the inherent amphiphilic molecular structure and pharmacological effects of ginsenoside Rg5, the prepared RPM enhances the water solubility and active targeting of PTX, inhibiting chemotherapy resistance in cancer cells. Moreover, the polymeric micelles demonstrated favorable anti-inflammatory and neuroprotective effects, providing ideas for the development of new clinical anti-PC preparations."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Polycaprolactone - Vitamin E TPGS micelles for delivery of paclitaxel: In vitro and in vivo evaluation. (PubMed, Int J Pharm ) - "Pharmacokinetics of PTX as part of PCL-TPGS showed a significant increase in its volume of distribution compared to PTX conventional formulation, Ebetaxel, which is in line with what was reported for clinical nano formulations of PTX, i.e., Abraxane, Genexol-PM, or Apealea. The findings of our studies indicate a significant potential for PCL-TPGS micelles to act as an effective system for solubilization and delivery of PTX."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

A Gene Agnostic Stem Cell Therapy for Mid-Stage Retinitis Pigmentosa Treatment (ASGCT 2024) - "In three distinct genetic RP models, sustained delivery of trophic factors by intravitreally injected allogeneic hRPCs safely preserved cone photoreceptors and visual function. Elucidating responsible protein agents and mechanisms enables optimizing potency. This platform technology may enable mutation-agnostic intervention amidst disease heterogeneity by restoring cone functions."

Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: NantPharma, LLC | Phase classification: P1b/2 ➔ P1/2 | N=64 ➔ 0 | Trial completion date: Dec 2024 ➔ Dec 2023 | Suspended ➔ Withdrawn | Trial primary completion date: Dec 2024 ➔ Dec 2023

Combination therapy • Enrollment change • Metastases • Phase classification • Trial completion date • Trial primary completion date • Trial withdrawal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Traditional healers working with primary care and mental health for early intervention in psychosis in young persons: protocol for the feasibility cluster randomised controlled trial. (PubMed, BMJ Open) - "Ethical approval has been obtained from Keele University Ethical Review Panel (ref: MH210177), Khyber Medical University Ethical Review Board (ref: DIR/KMU-EB/IG/001005) and National Bioethics Committee Pakistan (ref no...The results of THE HOPE feasibility trial will be reported in peer-reviewed journals and academic conferences and disseminated to local stakeholders and policymakers. ISRCTN75347421."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer (clinicaltrials.gov) - P=N/A | N=600 | Completed | Sponsor: Seoul National University Hospital | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Oncology • Ovarian Cancer • Solid Tumor

Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas. (ASCO 2023) - P2 | "Treatment of advanced pancreatic cancer with combination of GENEXOL-PM and gemcitabine was generally well tolerated and showed a favorable toxicity profile. In this study, efficacy results of combination regimen were comparable to that observed historically with albumin-bound paclitaxel and gemcitabine combination. This regimen demonstrated chemotherapeutic effects to warrant further development when used as first-line chemotherapy for advanced pancreatic cancer."

Clinical • Metastases • P2 data • Anemia • Gastrointestinal Cancer • Hepatology • Immunology • Neutropenia • Oncology • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pneumonia

Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study. (PubMed, Cancer Res Treat) - "Weekly administered Genexol-PM with carboplatin demonstrated an acceptable safety profile in gynecologic cancer patients. The recommended phase II dose of weekly Genexol-PM is up to 120 mg/m2 when combined with carboplatin."

Journal • P1 data • Fallopian Tube Cancer • Gynecologic Cancers • Immunology • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer

IGV-001: A Biologic-device Combination Product to Elicit Immunogenic Cell Death-associated Immune Responses Against Glioblastoma (FCI 2023) - "The lead product, IGV001, was evaluated in newly diagnosed glioblastoma (GBM) patients in a phase 1b study. Sequencing the T cell receptor Vβ CDR3 region in 8 clinical samples showed that clonal expansion in peripheral blood between 28d postIGV-001 and timepoints 90-150d positively correlated with OS (Spearman r=0.88, p<0.01). Key cytokines were found to be predictive of patient outcome via machine learning classification."

Immunogenic cell death • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacy. (PubMed, Drug Deliv Transl Res) - "In this study, we evaluated the effect of paclitaxel-loaded polymeric micelles (PTX-PMCs) and polymeric nanoparticles (PTX-PNPs) in a tumor stroma-mimicking 3D in vitro model. Altogether, this study shows that the efficacy of nanotherapeutics is challenged by stroma-induced poor penetration and development of resistant phenotype. Therefore, this tumor stroma-mimicking 3D model can provide an excellent platform to study penetration and effects of nanotherapeutics before in vivo studies."

IO biomarker • Journal • Preclinical • Stroma • Breast Cancer • Oncology • Solid Tumor • BCL2

Hypoxia-Responsive Stereocomplex Polymeric Micelles with Improved Drug Loading Inhibit Breast Cancer Metastasis in an Orthotopic Murine Model. (PubMed, ACS Appl Mater Interfaces) - "Taxane-loaded polymeric formulations, such as Genexol PM and Nanoxel M using poly(ethylene glycol)-poly(d,l-lactide) (PEG-PLA) micelles as drug carriers, have been approved for the treatment of metastatic breast cancer. In vivo results further showed that the micelles, especially at a high dose, inhibited the growth of the primary tumor and improved tumor pathological conditions, consequently remarkably inhibiting its metastasis to the lungs and liver, while not causing any systemic toxicity. Hypoxia-responsive stereocomplex micelles thus emerge as a reliable drug delivery system to treat breast cancer metastasis."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy. (PubMed, AAPS PharmSciTech) - "Compared with free ATO and the clinically used nanomedicine Genexol/PM, AATONP shows potent antitumor activity against a human HCC xenograft mouse model, leading to a higher tumor inhibition rate of 89.4% in HCC therapy. An albumin-embellished arsenic trioxide (ATO)-loaded polyethylene glycol-polycaprolactone-polyethyleneimine nanoparticle (AATONP) is designed to enhance tumor distribution and intratumor drug release of ATO for hepatocellular carcinoma therapy. AATONP can achieve enhanced tumor distribution via albumin-mediated transcytosis and exhibit intratumor drug release of ATO via tumor acidic microenvironment-response, leading to potent antitumor activity."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor